SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 208.65

Change

+3.05 (+1.48)%

Market Cap

N/A

Volume

3.14K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.50 (+1.13%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

+2.29 (+2.45%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.27 (+1.16%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.24 (+1.83%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.03 (+0.54%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.35 (+1.57%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.34 (+2.84%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-1.13 (-1.99%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.20 (+2.06%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.13 (-0.10%)

USD 12.26B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.26% 62% D 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.26% 64% D 60% D-
Trailing 12 Months  
Capital Gain -3.69% 19% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.69% 22% F 27% F
Trailing 5 Years  
Capital Gain 29.29% 40% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.29% 41% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 9.16% 62% D 62% D
Dividend Return 9.16% 61% D- 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.20% 69% C- 76% C+
Risk Adjusted Return 111.71% 95% A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike